Compare UGI & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGI | CYTK |
|---|---|---|
| Founded | 1940 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | UGI | CYTK |
|---|---|---|
| Price | $37.05 | $63.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $44.00 | ★ $82.38 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 147.20 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $7,287,000,000.00 | $87,211,000.00 |
| Revenue This Year | $21.37 | $346.43 |
| Revenue Next Year | $3.03 | $57.69 |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | 1.07 | ★ 2609.26 |
| 52 Week Low | $28.25 | $29.31 |
| 52 Week High | $39.59 | $70.98 |
| Indicator | UGI | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 50.68 |
| Support Level | $36.69 | $60.30 |
| Resistance Level | $37.82 | $65.25 |
| Average True Range (ATR) | 0.65 | 2.84 |
| MACD | -0.19 | 0.11 |
| Stochastic Oscillator | 24.44 | 60.08 |
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.